177 lines
38 KiB
Text
177 lines
38 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK612552">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK612552/?report=reader">
|
|
<meta name="ncbi_pagename" content="Elacestrant - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Elacestrant - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Efgartigimod/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/Elafibranor/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Elacestrant">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2025/02/25">
|
|
<meta name="citation_pmid" content="40043213">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK612552/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Elacestrant">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2025/02/25">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK612552/">
|
|
<meta name="description" content="Elacestrant is an estrogen receptor antagonist which is used for treatment of specific forms of refractory, advanced or metastatic breast cancer in postmenopausal women or adult men. Elacestrant has not been linked to elevations in serum aminotransferase levels during therapy or to cases of clinically apparent liver injury.">
|
|
<meta name="og:title" content="Elacestrant">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Elacestrant is an estrogen receptor antagonist which is used for treatment of specific forms of refractory, advanced or metastatic breast cancer in postmenopausal women or adult men. Elacestrant has not been linked to elevations in serum aminotransferase levels during therapy or to cases of clinically apparent liver injury.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK612552/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Elacestrant/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK612552/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8C500E7D7F6BA100000000011600E2.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK612552/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Efgartigimod/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Elacestrant</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/Elafibranor/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK612552/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK612552/&text=Elacestrant"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK612552/?report=classic">Switch to classic view</a><a href="/books/NBK612552/pdf/Bookshelf_NBK612552.pdf">PDF (94K)</a><a href="/books/NBK612552/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK612552%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8C500E7D7F6BA100000000011600E2.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK612552_"><span class="title" itemprop="name">Elacestrant</span></h1><p class="fm-aai"><a href="#_NBK612552_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="Elacestrant.OVERVIEW"><h2 id="_Elacestrant_OVERVIEW_">OVERVIEW</h2><div id="Elacestrant.Introduction"><h3>Introduction</h3><p>Elacestrant is an estrogen receptor antagonist which is used for treatment of specific forms of refractory, advanced or metastatic breast cancer in postmenopausal women or adult men. Elacestrant has not been linked to elevations in serum aminotransferase levels during therapy or to cases of clinically apparent liver injury.</p></div><div id="Elacestrant.Background"><h3>Background</h3><p>Elacestrant (el” a ses’ trant) is a small molecule, estrogen receptor (ER) degrader that is used to treat postmenopausal women or adult men with advanced or metastatic breast cancer that is positive for ER and negative for human epidermal growth factor 2 (HER2). Elacestrant was the first orally available estrogen receptor degrader, a previous similarly active drug was fulvestrant which requires intramuscular injections every 2 to 4 weeks. Elacestrant binds to the estrogen receptor alpha and leads to its degradation, making cells resistant to estrogen-stimulated cell proliferation. In registration trials, elacestrant improved progression-free survival in women with advanced or metastatic, ER-positive, and HER2-negative breast cancer after failure of conventional antiestrogen therapy. Post hoc analyses showed that the benefit from elacestrant was largely in women who harbored an ESR1 mutation and when it was approved for use in the United States in 2023, the formal indications were limited to women with cancers and this specific mutation who have had disease progression following endocrine therapy. Elacestrant is available in tablets of 86 and 345 mg under the brand name Orserdu. The recommended dose is 345 mg daily to be continued until disease progression or unacceptable toxicity occurs. The dose can be decreased for adverse events or for preexisting moderate degrees of hepatic dysfunction. Common side effects include musculoskeletal pain, nausea, vomiting, diarrhea, abdominal pain, headache, and hot flushes. Laboratory abnormalities during elacestrant therapy can include increases in cholesterol and triglyceride, creatinine, and aminotransferase levels and decreases in hemoglobin and sodium. Less common but potentially severe adverse events include severe dyslipidemia and embryo-fetal toxicity.</p></div><div id="Elacestrant.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In the major registration trial of elacestrant as therapy of breast cancer, serum ALT elevations arose in similar proportions of those on elacestrant as of the controls receiving “standard of care” (9% vs 10%) and were above 5 times the upper limit of normal in 2.1% vs 0.9% of controls. The elevations were transient and without symptoms or jaundice. No patient developed clinically apparent liver injury. Since its approval and more widespread use, there have been no published reports of hepatotoxicity attributed to elacestrant therapy.</p><p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p></div><div id="Elacestrant.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism by which elacestrant might cause liver injury is not known. Elacestrant is a complex small molecule (a tetrahydronaphthalene) and is metabolized in the liver, predominantly by CYP 3A4. Elacestrant is susceptible to drug-drug interactions; moderate inhibitors of CYP 3A4 can cause increases in plasma levels to potentially toxic levels, and moderate inducers of CYP 3A4 can cause decreases in plasma levels to potentially subtherapeutic levels.</p></div><div id="Elacestrant.Outcome_and_Management"><h3>Outcome and Management</h3><p>There is no evidence that elacestrant therapy can cause severe elevations in serum enzymes or lead to clinically apparent liver injury.</p><p>Drug Class: <a href="/books/n/livertox/AntineoplasticAgents/?report=reader">Antineoplastic Agents</a>, <a href="/books/n/livertox/AromataseInhibitors/?report=reader">Antiestrogens</a></p><p>Other Selective Estrogen Receptor Degraders: <a href="/books/n/livertox/Fulvestrant/?report=reader">Fulvestrant</a></p><p>Other Selective Estrogen Receptor Modulators: <a href="/books/n/livertox/SERMS/?report=reader">Raloxifene</a>, <a href="/books/n/livertox/Tamoxifen/?report=reader">Tamoxifen</a>, <a href="/books/n/livertox/Toremifene/?report=reader">Toremifene</a></p></div></div><div id="Elacestrant.PRODUCT_INFORMATION"><h2 id="_Elacestrant_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Elacestrant – Orserdu®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Antineoplastic Agents, Antiestrogens</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Elacestrant" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Elacestrant.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Elacestrant_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figElacestrantTc"><a href="/books/NBK612552/table/Elacestrant.Tc/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobElacestrantTc"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="Elacestrant.Tc"><a href="/books/NBK612552/table/Elacestrant.Tc/?report=objectonly" target="object" rid-ob="figobElacestrantTc">Table</a></h4></div></div></div><div id="Elacestrant.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Elacestrant_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 25 February 2025</p><p>Abbreviations: ER, estrogen receptor; HER2, human epithelial growth factor 2.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Elacestrant.REF.zimmerman.1999">Zimmerman HJ. Hepatotoxic effects of oncotherapeutic and immunosuppressive agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 699.<div><i>(Expert review of hepatotoxicity published in 1999, before the availability of elacestrant and other estrogen receptor modulators and degraders).</i></div></div></li><li><div class="bk_ref" id="Elacestrant.REF.chitturi.2013">Chitturi S, Farrell GC. Estrogen receptor antagonists. Adverse effects of hormones and hormone antagonists on the liver. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 610-2.<div><i>(Review of hepatotoxicity of estrogens and antiestrogens discusses tamoxifen but not elacestrant or fulvestrant).</i></div></div></li><li><div class="bk_ref" id="Elacestrant.REF.isaacs.2018">Isaacs C, Wellstein A, Riegel AT. Hormones and related agents in the therapy of cancer. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1237-1248.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Elacestrant.REF4">FDA. 2023. Multi-Discipline Review. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217639Orig1s000MultidisciplineR.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.accessdata<wbr style="display:inline-block"></wbr>​.fda.gov/drugsatfda_docs<wbr style="display:inline-block"></wbr>​/nda/2023/217639Orig1s000MultidisciplineR.pdf</a><div><i>(FDA website with the product labels and integrated review of the data on efficacy and safety provided by the sponsor in support of approval of elacestrant as therapy of refractory and advanced, ER-positive breast cancer, mentions that ALT elevations were less frequent with elacestrant therapy than standard of care [17% vs 24%] including values greater than 5 times ULN [0.4% vs 1.3%], and there were no cases of clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="Elacestrant.REF.chalasani.2015.1340">Chalasani
|
|
N, Bonkovsky
|
|
HL, Fontana
|
|
R, Lee
|
|
W, Stolz
|
|
A, Talwalkar
|
|
J, Reddy
|
|
KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study.
|
|
Gastroenterology
|
|
2015; 148: 1340-52.e7.
|
|
[<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25754159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, no cases were attributed to elacestrant).</i></div></div></li><li><div class="bk_ref" id="Elacestrant.REF.conlan.2020.675">Conlan
|
|
MG, de Vries
|
|
EFJ, Glaudemans
|
|
A, Wang
|
|
Y, Troy
|
|
S. Pharmacokinetic and pharmacodynamic studies of elacestrant, a novel oral selective estrogen receptor degrader, in healthy post-menopausal women.
|
|
Eur J Drug Metab Pharmacokinet.
|
|
2020; 45:675-689.
|
|
[<a href="/pmc/articles/PMC7511284/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7511284</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32661909" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32661909</span></a>]<div><i>(In phase 1 trials in 140 healthy, postmenopausal women, elacestrant demonstrated robust occupancy of estrogen receptors and acceptable tolerance, the most frequent adverse events being nausea, dyspepsia, vomiting, abdominal pain, esophageal pain, salivary hypersecretion, and diarrhea; and “there were no clinically significant changes in laboratory tests”).</i></div></div></li><li><div class="bk_ref" id="Elacestrant.REF.jager.2020.97">Jager
|
|
A, de Vries
|
|
EGE, der Houven van Oordt
|
|
CWM, Neven
|
|
P, Venema
|
|
CM, Glaudemans
|
|
AWJM, et al.
|
|
A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using <sup>18</sup>F-FES PET/CT imaging.
|
|
Breast Cancer Res.
|
|
2020; 22:97.
|
|
[<a href="/pmc/articles/PMC7488419/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7488419</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32912274" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32912274</span></a>]<div><i>(Among 16 patients with advanced ER-positive breast cancer treated with elacestrant [200 or 400 mg] once daily for 14 days followed by continuation at the higher dose, PET scanning at 14 days demonstrated a decrease in estrogen receptor activity, and continued treatment showed antitumor activity with acceptable toxicity; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Elacestrant.REF.bardia.2021.1360">Bardia
|
|
A, Kaklamani
|
|
V, Wilks
|
|
S, Weise
|
|
A, Richards
|
|
D, Harb
|
|
W, Osborne
|
|
C, et al.
|
|
Phase I study of elacestrant (RAD1901), a novel selective estrogen receptor degrader, in ER-positive, HER2-negative advanced breast cancer.
|
|
J Clin Oncol.
|
|
2021;39: 1360-1370.
|
|
[<a href="/pmc/articles/PMC8078341/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8078341</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33513026" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33513026</span></a>]<div><i>(Among 57 postmenopausal, heavily pretreated women with advanced ER-positive, HER2-negative breast cancer treated with elacestrant [mostly with 400 mg daily], clinical responses occurred in 43% by 24 weeks, and adverse events were largely mild-to-moderate gastrointestinal complaints of nausea and vomiting, dyspepsia, abdominal pain, and fatigue, while ALT elevations arose in 18% and were above 5 times ULN in 4%, none were associated with jaundice or symptoms).</i></div></div></li><li><div class="bk_ref" id="Elacestrant.REF.bidard.2022.3246">Bidard
|
|
FC, Kaklamani
|
|
VG, Neven
|
|
P, Streich
|
|
G, Montero
|
|
AJ, Forget
|
|
F, Mouret-Reynier
|
|
MA, et al.
|
|
Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD Trial.
|
|
J Clin Oncol.
|
|
2022; 40:3246-3256.
|
|
[<a href="/pmc/articles/PMC9553388/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9553388</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35584336" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35584336</span></a>]<div><i>(Among 477 patients with advanced and refractory ER-positive, HER2-negative breast cancer treated with oral elacestrant [400 mg daily] vs standard of care, median progression-free survival at 1 year was 22% vs 8%, while adverse event rates were 92% vs 86%, the most frequent events being nausea [35% vs 19%], fatigue [19% vs 19%], vomiting [19% vs 8%], decreased appetite [15% vs 9%], and arthralgia [14% vs 16%]; ALT elevations arising in 9% vs 10% and were above 5 times ULN in 2% vs 0.9% ).</i></div></div></li><li><div class="bk_ref" id="Elacestrant.REF.hoy.2023.555">Hoy
|
|
SM. Elacestrant: first approval.
|
|
Drugs.
|
|
2023;83:555-561.
|
|
[<a href="/pmc/articles/PMC10667141/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10667141</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37060385" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37060385</span></a>]<div><i>(Review of the mechanism of action, history of development, pharmacology, clinical efficacy, and toxicity of elacestrant shortly after its approval for use in breast cancer in the US, mentions the common gastrointestinal adverse events but does not mention ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Elacestrant.REF.shah.2024.1193">Shah
|
|
M, Lingam
|
|
H, Gao
|
|
X, Gittleman
|
|
H, Fiero
|
|
MH, Krol
|
|
D, Biel
|
|
N, et al.
|
|
US Food and Drug Administration approval summary: elacestrant for estrogen receptor-positive, human epidermal growth factor receptor 2-negative, <em>ESR</em>1-mutated advanced or metastatic breast cancer.
|
|
J Clin Oncol.
|
|
2024;42:1193-1201.
|
|
[<a href="/pmc/articles/PMC11003513/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC11003513</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38381994" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 38381994</span></a>]<div><i>(Summary of the efficacy and safety data that supported the FDA decision to approve elacestrant as therapy of refractory, advanced or metastatic breast cancer, discusses the analysis of a safety cohort of 467 patients in whom there were no deaths, but discontinuations occurred in 6% of the treated vs 4.3% of standard of care controls; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Elacestrant.REF.bardia.2024.4299">Bardia
|
|
A, Cortés
|
|
J, Bidard
|
|
FC, Neven
|
|
P, Garcia-Sáenz
|
|
J, Aftimos
|
|
P, O'Shaughnessy
|
|
J, et al.
|
|
Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups.
|
|
Clin Cancer Res.
|
|
2024;30:4299-4309.
|
|
[<a href="/pmc/articles/PMC11443208/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC11443208</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39087959" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 39087959</span></a>]<div><i>(Among 477 patients with advanced and refractory ER-positive, HER2-negative breast cancer treated with oral elacestrant [400 mg daily] vs standard of care [Bardia 2022], subgroup analyses demonstrated improvements in progression-free survival was improved regardless of presence of ER mutations or previous therapies, and adverse event rates in these subgroups were similar, ALT elevations arising in 5% vs 12% [elacestrant vs standard of care] and were above 5 times ULN in 1.0% vs <1.0% ).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK612552_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">February 25, 2025</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Elacestrant. [Updated 2025 Feb 25].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Efgartigimod/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/Elafibranor/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobElacestrantTc"><div id="Elacestrant.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK612552/table/Elacestrant.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Elacestrant.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Elacestrant.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Elacestrant.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Elacestrant.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Elacestrant.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Elacestrant.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Elacestrant</td><td headers="hd_h_Elacestrant.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/316908472" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">722533-56-4</a>
|
|
</td><td headers="hd_h_Elacestrant.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C30-H38-N2-O2</td><td headers="hd_h_Elacestrant.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/316908472" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=316908472" alt="image 316908472 in the ncbi pubchem database" /></a>
|
|
</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|